NCT05183048View on ClinicalTrials.gov

Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

[89Zr]Panitumumab Tracer

All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.

Trial Locations (1)

35249

RECRUITING

UAB, Birmingham

All Listed Sponsors

lead

University of Alabama at Birmingham

OTHER

NCT05183048 - Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter